Novo Nordisk invests additional US$100m in China
Opens bigger research and development centre
Novo Nordisk has reaffirmed its long-term commitment to China by investing an additional US$100m to expand its state-of-the-art science facilities in Beijing by 12,000m2.
The Danish diabetes drug specialist says it will add 70 new scientists to its workforce in China, taking the total to 200, with extra space available to accommodate additional future growth. With this expansion, Novo Nordisk also fulfils its key strategic objective to ensure a full range of protein research capabilities in China.
Mads Krogsgaard Thomsen, chief science officer and executive vp, Novo Nordisk, said: ‘We see the investment in this new r&d facility as a win-win opportunity for both Novo Nordisk and China. Novo Nordisk recognises the strong science being performed in China and we want to bring innovation from Chinese scientists into our company to help tackle the growing burden of diabetes and other chronic diseases throughout the world.’
The site in Beijing has already made a significant contribution to the company’s research and development portfolio in both diabetes and biopharmaceutical target disease areas. The new, expanded facility will enable stronger contributions from the science team in China across Novo Nordisk’s protein technology, biology and pharmacology research activities.
Novo Nordisk has had a presence in China since 1994. The headquarters and r&d centre are in Beijing, with the production site in Tianjin, and local offices in Shanghai, Guangzhou, Shenyang, Wuhan, Jinan, Hangzhou, Chengdu, Hong Kong and Taiwan. Currently the firm employs around 3,000 people in China.
